Logo image of XFOR

X4 PHARMACEUTICALS INC (XFOR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XFOR - US98420X2027 - Common Stock

3.96 USD
+0.12 (+3.13%)
Last: 1/6/2026, 4:30:02 PM
Fundamental Rating

2

Taking everything into account, XFOR scores 2 out of 10 in our fundamental rating. XFOR was compared to 530 industry peers in the Biotechnology industry. XFOR has a bad profitability rating. Also its financial health evaluation is rather negative. XFOR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XFOR has reported negative net income.
XFOR had a negative operating cash flow in the past year.
XFOR had negative earnings in each of the past 5 years.
XFOR had a negative operating cash flow in each of the past 5 years.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

XFOR has a Return On Assets (-58.14%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -154.33%, XFOR is doing worse than 64.15% of the companies in the same industry.
Industry RankSector Rank
ROA -58.14%
ROE -154.33%
ROIC N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

XFOR's Gross Margin of 83.24% is amongst the best of the industry. XFOR outperforms 86.42% of its industry peers.
The Profit Margin and Operating Margin are not available for XFOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

3

2. Health

2.1 Basic Checks

XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
XFOR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XFOR has been increased compared to 5 years ago.
The debt/assets ratio for XFOR is higher compared to a year ago.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -3.89, we must say that XFOR is in the distress zone and has some risk of bankruptcy.
XFOR has a Altman-Z score of -3.89. This is comparable to the rest of the industry: XFOR outperforms 42.83% of its industry peers.
XFOR has a Debt/Equity ratio of 1.23. This is a high value indicating a heavy dependency on external financing.
XFOR has a worse Debt to Equity ratio (1.23) than 75.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Altman-Z -3.89
ROIC/WACCN/A
WACC9.27%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

XFOR has a Current Ratio of 5.65. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
XFOR's Current ratio of 5.65 is in line compared to the rest of the industry. XFOR outperforms 59.43% of its industry peers.
A Quick Ratio of 5.48 indicates that XFOR has no problem at all paying its short term obligations.
With a decent Quick ratio value of 5.48, XFOR is doing good in the industry, outperforming 60.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.65
Quick Ratio 5.48
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

XFOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.70%, which is quite impressive.
The Revenue has grown by 2925.73% in the past year. This is a very strong growth!
EPS 1Y (TTM)44.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.22%
Revenue 1Y (TTM)2925.73%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%215.18%

3.2 Future

Based on estimates for the next years, XFOR will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.15% on average per year.
XFOR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 152.19% yearly.
EPS Next Y86.91%
EPS Next 2Y39.58%
EPS Next 3Y24.95%
EPS Next 5Y15.15%
Revenue Next Year1476.4%
Revenue Next 2Y148.43%
Revenue Next 3Y141.61%
Revenue Next 5Y152.19%

3.3 Evolution

XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XFOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XFOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

XFOR's earnings are expected to grow with 24.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.58%
EPS Next 3Y24.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XFOR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (1/6/2026, 4:30:02 PM)

3.96

+0.12 (+3.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners24.05%
Inst Owner Change0%
Ins Owners1.07%
Ins Owner Change10.75%
Market Cap346.26M
Revenue(TTM)33.98M
Net Income(TTM)-95.09M
Analysts84
Price Target8.16 (106.06%)
Short Float %3.93%
Short Ratio2.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.86%
Min EPS beat(2)21.58%
Max EPS beat(2)26.15%
EPS beat(4)3
Avg EPS beat(4)34.14%
Min EPS beat(4)-12.04%
Max EPS beat(4)100.88%
EPS beat(8)4
Avg EPS beat(8)-148.51%
EPS beat(12)6
Avg EPS beat(12)-98.57%
EPS beat(16)8
Avg EPS beat(16)-75.33%
Revenue beat(2)1
Avg Revenue beat(2)2.37%
Min Revenue beat(2)-15.27%
Max Revenue beat(2)20.01%
Revenue beat(4)3
Avg Revenue beat(4)338.32%
Min Revenue beat(4)-15.27%
Max Revenue beat(4)1313.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.05%
PT rev (3m)-8.05%
EPS NQ rev (1m)-1.33%
EPS NQ rev (3m)39.68%
EPS NY rev (1m)14.38%
EPS NY rev (3m)25.97%
Revenue NQ rev (1m)-12.82%
Revenue NQ rev (3m)-32.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.19
P/FCF N/A
P/OCF N/A
P/B 5.62
P/tB 9.94
EV/EBITDA N/A
EPS(TTM)-10.12
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0.39
BVpS0.7
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.14%
ROE -154.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.24%
FCFM N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 229.16%
Cap/Sales 8.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.65
Quick Ratio 5.48
Altman-Z -3.89
F-Score3
WACC9.27%
ROIC/WACCN/A
Cap/Depr(3y)318.09%
Cap/Depr(5y)293.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.22%
EPS Next Y86.91%
EPS Next 2Y39.58%
EPS Next 3Y24.95%
EPS Next 5Y15.15%
Revenue 1Y (TTM)2925.73%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%215.18%
Revenue Next Year1476.4%
Revenue Next 2Y148.43%
Revenue Next 3Y141.61%
Revenue Next 5Y152.19%
EBIT growth 1Y24.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.33%
OCF growth 3YN/A
OCF growth 5YN/A

X4 PHARMACEUTICALS INC / XFOR FAQ

What is the ChartMill fundamental rating of X4 PHARMACEUTICALS INC (XFOR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to XFOR.


What is the valuation status for XFOR stock?

ChartMill assigns a valuation rating of 1 / 10 to X4 PHARMACEUTICALS INC (XFOR). This can be considered as Overvalued.


What is the profitability of XFOR stock?

X4 PHARMACEUTICALS INC (XFOR) has a profitability rating of 1 / 10.


What is the earnings growth outlook for X4 PHARMACEUTICALS INC?

The Earnings per Share (EPS) of X4 PHARMACEUTICALS INC (XFOR) is expected to grow by 86.91% in the next year.